Ryota Nakamura
Overview
Explore the profile of Ryota Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
167
Citations
1054
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Morita K, Nakamura R, Ban M, Yoshimura S, Tsunekawa Y, Kato H, et al.
JPRAS Open
. 2024 Aug;
41:260-264.
PMID: 39170094
Reconstructing extensive defects in the hip and groin region is challenging. Although the technique of wrapping the flaps is often chosen, achieving effective coverage of defects is difficult because of...
12.
Morimoto K, Hamashima R, Yamada T, Yokoyama T, Kobayashi T, Tsuyuguchi K, et al.
Thorac Cancer
. 2024 Aug;
15(26):1882-1888.
PMID: 39090758
Background: Advances in anticancer drugs for lung cancer (LC) have improved the prognosis of LC. Chronic pulmonary aspergillosis (CPA) is a progressive and often exacerbating respiratory disease with a poor...
13.
Nakamura R, Yamada T, Tokuda S, Morimoto K, Katayama Y, Matsui Y, et al.
Cancer Lett
. 2024 Jul;
598:217124.
PMID: 39059573
We previously reported that combined therapy with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib and AXL inhibitor ONO-7475 is effective in preventing the survival of drug-tolerant cells in...
14.
Commey K, Enaka A, Nakamura R, Yamamoto A, Tsukigawa K, Nishi K, et al.
Toxins (Basel)
. 2024 Jul;
16(7).
PMID: 39057956
The characteristic accumulation of circulating uremic toxins, such as indoxyl sulfate (IS), in chronic kidney disease (CKD) further exacerbates the disease progression. The gut microbiota, particularly gut bacterial-specific enzymes, represents...
15.
Rahman M, Nakamura R, Islam M, Alam M, Azmat S, Sato M
Healthcare (Basel)
. 2024 Jul;
12(14).
PMID: 39057545
The aim of this multi-country, cluster-randomized trial is to test the impact of pharmacy-based health promotion to reduce the blood pressure of individuals with hypertension over a 12-month period in...
16.
Matsui Y, Yamada T, Katayama Y, Hirai S, Sawada R, Tachibana Y, et al.
Cancer Sci
. 2024 Jul;
115(10):3333-3345.
PMID: 39039802
Lazertinib, a novel third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), demonstrates marked efficacy in EGFR-mutant lung cancer. However, resistance commonly develops, prompting consideration of therapeutic strategies to overcome...
17.
Kaneko H, Korenaga R, Nakamura R, Kawai S, Ando T, Shiroishi M
J Mol Recognit
. 2024 Jun;
37(5):e3098.
PMID: 38924170
Doxepin is an antihistamine and tricyclic antidepressant that binds to the histamine H receptor (HR) with high affinity. Doxepin is an 85:15 mixture of the E- and Z-isomers. The Z-isomer...
18.
Maezawa Y, Taguchi M, Kawakami T, Inui T, Okauchi S, Numata T, et al.
Tuberk Toraks
. 2024 Jun;
72(2):107-113.
PMID: 38869202
Introduction: In addition to the two common epidermal growth factor receptor (EGFR) mutations, there are many uncommon mutations. Due to the high number of uncommon types, as well as the...
19.
Kato H, Kawaguchi Y, Saito K, Hamamoto S, Nakamura R, Ohashi K, et al.
J Dermatol
. 2024 Jun;
51(12):1698-1701.
PMID: 38863214
Necrotizing fasciitis is a fatal, soft tissue infection of the skin that requires prompt treatment. Historically, most cases have been attributed to group A beta-hemolytic Streptococcus infection. However, in recent...
20.
Ano S, Kikuchi N, Okauchi S, Numata T, Nakamura R, Shiozawa T, et al.
Anticancer Res
. 2024 May;
44(6):2725-2730.
PMID: 38821613
Background/aim: Atezolizumab, an anti-PD-L1 antibody, has been increasingly administered in combination with chemotherapy to patients with small cell lung cancer (SCLC). This study aimed to determine how patients with extensive...